• Disease
  • Advanced
  • Advanced Melanoma
  • Frank Stephen Hodi

    Prominent publications by Frank Stephen Hodi

    KOL Index score: 31763

    BACKGROUND: Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.

    METHODS: In this phase 3 trial, eligible patients were aged 18 years or older with previously ...

    Also Ranks for: Nivolumab Ipilimumab |  advanced melanoma |  3 trial |  progressionfree survival |  hazard ratio
    KOL Index score: 25114

    BACKGROUND: Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced ...

    Also Ranks for: Ipilimumab Patients |  advanced melanoma |  survival outcomes |  combined nivolumab |  phase 2
    KOL Index score: 23158

    BACKGROUND: Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma.

    METHODS: We carried out a randomised phase 2 trial of patients aged 18 years or older from 73 hospitals, clinics, and academic medical centres in 12 countries who had confirmed ...

    Also Ranks for: Patients Pembrolizumab |  2 trial |  choice chemotherapy |  treatment ipilimumab |  progressionfree survival
    KOL Index score: 19651

    Importance: Programmed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potentially life-threatening adverse event. Little is known about its incidence across different tumor types and treatment regimens.

    Objective: To compare the incidence of PD-1 inhibitor-related pneumonitis among different tumor types and therapeutic regimens.

    Data Sources: A PubMed search through November 10, 2015, and a review of references from relevant articles. For the ...

    Also Ranks for: Incidence Pneumonitis |  cell death |  combination therapy |  advanced cancer |  nsclc rcc
    KOL Index score: 19577

    BACKGROUND: Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma.

    METHODS: In this randomised, controlled, open-label, phase 3 trial, we recruited patients at 90 sites in 14 ...

    Also Ranks for: 3 Trial |  advanced melanoma |  patients icc |  objective response |  braf inhibitor
    KOL Index score: 18737

    BACKGROUND: Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab.

    METHODS: In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA. Eligible patients were aged ...

    Also Ranks for: Dose Pembrolizumab |  advanced melanoma |  monoclonal antibodies |  ipilimumab patients |  objective response
    KOL Index score: 18478

    BACKGROUND: Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events. We assessed whether sequential administration of nivolumab followed by ipilimumab, or the reverse sequence, could improve safety without compromising efficacy.

    METHODS: We did this randomised, open-label, phase 2 study at nine academic medical centres in the ...

    Also Ranks for: Ipilimumab Nivolumab |  sequential administration |  advanced melanoma |  median followup |  3 weeks
    KOL Index score: 18472

    BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial.

    METHODS: We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram ...

    Also Ranks for: Advanced Melanoma |  combined nivolumab |  3 kilogram |  ipilimumab patients |  2 weeks
    KOL Index score: 16623

    BACKGROUND: Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.

    METHODS: We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed ...

    Also Ranks for: Ipilimumab Nivolumab |  advanced melanoma |  3 weeks |  hazard ratio |  5 years
    KOL Index score: 15906

    IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.

    OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma.

    DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study ...

    Also Ranks for: Advanced Melanoma |  tumor response |  monoclonal antibodies |  rate treatment |  measurable disease
    KOL Index score: 15844

    Importance: If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of immune checkpoint inhibitor (ICI) regimens are unknown.

    Objective: To compare the incidence and risk of endocrine AEs following treatment with US Food and Drug Administration-approved ICI regimens.

    Data Sources: A PubMed search through July 18, 2016, using the following keywords was performed: "ipilimumab," "MDX-010," ...

    Also Ranks for: Endocrine Dysfunction |  combination therapy |  hypothyroidism hyperthyroidism |  patients ipilimumab |  incidence risk
    KOL Index score: 15733

    BACKGROUND: Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab improves survival in patients with advanced melanoma. We aimed to investigate the safety and activity of this drug specifically in patients with brain metastases.

    METHODS: Between July 31, 2008, and June 3, 2009, we enrolled patients with melanoma and brain metastases from ten US centres who were older than 16 years into two parallel cohorts. ...

    Also Ranks for: Patients Cohort |  brain metastases |  2 trial |  disease control |  advanced melanoma
    KOL Index score: 15542

    PURPOSE: Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops. Interest remains in combining targeted and immune therapies to overcome resistance and improve durability of clinical benefit. One mechanism of evading immune destruction is programmed death-1-ligand 1 (PD-L1) expression by tumors that results in potent antitumor immune suppression.

    EXPERIMENTAL DESIGN: BRAFi-resistant ...

    Also Ranks for: Melanoma Cells |  l1 expression |  brafi resistance |  braf inhibition |  protein kinase
    KOL Index score: 15529

    BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.

    METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or ...

    Also Ranks for: Ipilimumab Gp100 |  metastatic melanoma |  patients adverse events |  monoclonal antigens |  hazard ratio
    KOL Index score: 15449

    BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.

    METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with ...

    Also Ranks for: Ipilimumab Monotherapy |  untreated melanoma |  nivolumab combination |  objective response |  rate progression


    Frank Stephen Hodi: Influence Statistics

    Sample of concepts for which Frank Stephen Hodi is among the top experts in the world.
    Concept World rank
    melanoma tumor endothelial #1
    median melanoma #1
    iraes corticosteroids #1
    synergistic competitors #1
    43 pts #1
    nct01633970 atezolizumab #1
    immune ctla4 #1
    cd8 cellular responses #1
    potent functional capability #1
    osresults #1
    incidence selected grade #1
    120 patients nivolumab #1
    mecom mll2 #1
    potential biomarker response #1
    33 months 90 #1
    monoclonal autoimmunity ctla4 #1
    nivoipi nivo #1
    patients pneumonitis flare #1
    development symptomatic pneumonitis #1
    atezo cb #1
    radiation 14 #1
    ipilimumab multicentre #1
    metastatic melanoma atezolizumab #1
    intracranial disease discontinuation #1
    cohort 2 treme #1
    mucosal melanoma icb #1
    unique cytologic features #1
    brafi therapy meki #1
    ict neoplasms carcinoma #1
    biopsies car cells #1
    95 dsgpa #1
    treated patients gal1 #1
    cxcl10 vegf neutralization #1
    icpi therapy #1
    gas reduced benefit #1
    gm ipigm #1
    events nivolumab #1
    adas ly3415244 #1
    nct01783938 #1
    hdi e1609 #1
    radiation field radiotherapy #1
    157 months 90 #1
    20 increase baseline #1
    kit borr #1
    radiologic heterogeneity #1
    kilogram 3 weeks #1
    cancer preexisting ibd #1
    impact glucocorticoid therapy #1
    2016 aacr #1
    ipilimumab 14 20 #1

    Key People For Advanced Melanoma

    Top KOLs in the world
    Dirk Schadendorf
    melanoma patients advisory consultancy braf v600
    Caroline Robert
    advanced melanoma braf v600 advisory consultancy
    Frank Stephen Hodi
    advanced melanoma brain metastases nivolumab ipilimumab
    Reinhard G Dummer
    metastatic melanoma cutaneous lymphomas advisory consultancy
    Jean Jacques Grob
    advisory consultancy advanced melanoma grant funding
    Jeffrey S Weber
    metastatic melanoma advisory consultancy complete resection

    Frank Stephen Hodi:Expert Impact

    Concepts for whichFrank Stephen Hodihas direct influence:Advanced melanoma,  Metastatic melanoma,  Melanoma patients,  Brain metastases,  Mucosal melanoma,  Patients advanced melanoma,  Nivolumab ipilimumab,  Solid tumors.

    Frank Stephen Hodi:KOL impact

    Concepts related to the work of other authors for whichfor which Frank Stephen Hodi has influence:Immune checkpoint inhibitors,  Metastatic melanoma,  Lung cancer,  Tumor microenvironment,  Brain metastases,  Pdl1 expression,  Hepatocellular carcinoma.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Dana-Farber Cancer Institute, Boston, MA; | Dana Farber Cancer Institute, Boston, Massachusetts, USA | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA | Medical Oncology, Dana-Farber Cancer Institute, Boston,